

HARENBURG THOMAS A
Form SC 13D/A
June 11, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

(Amendment No. 2)

Under the Securities Exchange Act of 1934
BIOANALYTICAL SYSTEMS INC

(Name of Issuer)

Common Stock
(Title of Class of Securities)

09058M-10-3

(CUSIP Number)

THOMAS A HARENBURG
206 N MAIN ST. PO BOX 1069
OSHKOSH WI 54903

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

June 11, 2009

(Date of Event which Requires
Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box x

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D/A

CUSIP No. 09058M-10-3

Page 2 of 5 Pages

1 NAME OF REPORTING PERSON
 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
 THOMAS A HARENBURG

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)
 (b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
 INVESTMENT FUNDS

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
 US

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER	155,307
	8	SHARED VOTING POWER	121,460
	9	SOLE DISPOSITIVE POWER	155,307
	10	SHARED DISPOSITIVE POWER	121,460

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 276,767

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.63%

14 TYPE OF REPORTING PERSON
INDIVIDUAL INVESTOR

Page 3 of 5

Item 1. Security and Issuer.

This statement on Schedule 13D (“Schedule 13D”) relates to 276,767 shares of common stock, of BIOANALYTICAL SYSTEMS AN INDIANA corporation (the “Issuer”), whose principal executive offices are located at 2701 KENT AVE., WEST LAFAYETTE, IN 47906.

Item 2. Identity and Background.

(a) This Schedule 13D is filed by THOMAS A HARENBURG who is referred to herein as the “Reporting Person.”

(b) The Reporting Person’s business address is 206 N MAIN ST., OSHKOSH, WI 54901.

(c) Mr. HARENBURG IS THE PRESIDENT OF CARL M HENNIG Inc.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person has not been a party to any other civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) United States of America.

Item 3. Source and Amount of Funds or Other Consideration.

INVESTMENT FUNDS

Item 4. Purpose of Transaction.

REQUESTING BOARD REPRESENTATION 1 OF 5 EXISTING SEATS

Page 4 of 5

Item 5. Interest in Securities of the Issuer.

(a) The Reporting Person may be deemed to be the beneficial owner of 276,767 shares of Common Stock. Such 276,767 shares represent approximately 5.63% of the outstanding shares of Common Stock.

(b) The Reporting Person has the sole power to vote or to direct the vote or to dispose or to direct the disposition of 155,307 shares.

(c) The Reporting Person received all of shares in the issuer pursuant to the conversion of stock options.

(d) Not applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Not applicable.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.2 - Letter to the Board of Directors of Bioanalytical Systems

Page 5 of 5
Signatures

After reasonable inquiry and to the best of the knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 11, 2009

/s/ THOMAS A HARENBURG
THOMAS A HARENBURG
